CO6602157A2 - Combinacion farmaceutica - Google Patents

Combinacion farmaceutica

Info

Publication number
CO6602157A2
CO6602157A2 CO12158816A CO12158816A CO6602157A2 CO 6602157 A2 CO6602157 A2 CO 6602157A2 CO 12158816 A CO12158816 A CO 12158816A CO 12158816 A CO12158816 A CO 12158816A CO 6602157 A2 CO6602157 A2 CO 6602157A2
Authority
CO
Colombia
Prior art keywords
components
administered
combination
mammal
component
Prior art date
Application number
CO12158816A
Other languages
English (en)
Spanish (es)
Inventor
Klaus Schiene
Petra Bloms-Fluke
Original Assignee
Gruenenthal Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42395008&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6602157(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gruenenthal Chemie filed Critical Gruenenthal Chemie
Publication of CO6602157A2 publication Critical patent/CO6602157A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CO12158816A 2010-06-15 2012-09-14 Combinacion farmaceutica CO6602157A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10006202 2010-06-15

Publications (1)

Publication Number Publication Date
CO6602157A2 true CO6602157A2 (es) 2013-01-18

Family

ID=42395008

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12158816A CO6602157A2 (es) 2010-06-15 2012-09-14 Combinacion farmaceutica

Country Status (29)

Country Link
US (3) US8846765B2 (OSRAM)
EP (2) EP2992877A1 (OSRAM)
JP (3) JP6133772B2 (OSRAM)
KR (1) KR101831616B1 (OSRAM)
CN (1) CN103108631B (OSRAM)
AR (1) AR081931A1 (OSRAM)
AU (2) AU2011267474B2 (OSRAM)
BR (1) BR112012031836A2 (OSRAM)
CA (1) CA2796774C (OSRAM)
CL (1) CL2012002551A1 (OSRAM)
CO (1) CO6602157A2 (OSRAM)
CY (1) CY1117118T1 (OSRAM)
DK (1) DK2582366T3 (OSRAM)
EC (2) ECSP12012217A (OSRAM)
ES (1) ES2560676T3 (OSRAM)
HK (1) HK1215787A1 (OSRAM)
HR (1) HRP20151327T1 (OSRAM)
HU (1) HUE026619T2 (OSRAM)
IL (1) IL221926A (OSRAM)
MX (1) MX2012014482A (OSRAM)
NZ (1) NZ602625A (OSRAM)
PE (2) PE20130243A1 (OSRAM)
PL (1) PL2582366T3 (OSRAM)
PT (1) PT2582366E (OSRAM)
RS (1) RS54439B1 (OSRAM)
RU (2) RU2589692C2 (OSRAM)
SI (1) SI2582366T1 (OSRAM)
WO (1) WO2011157391A1 (OSRAM)
ZA (1) ZA201208646B (OSRAM)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8846765B2 (en) 2010-06-15 2014-09-30 Gruenenthal Gmbh Pharmaceutical combination
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
CN104519878A (zh) * 2012-03-12 2015-04-15 詹森药业有限公司 用于治疗顽固性或难治性抑郁症的艾氯胺酮
RS59687B1 (sr) * 2013-01-22 2020-01-31 Vistagen Therapeutics Inc Oblici doziranja i terapeutske primene l-4-hlorkinurenina
ES2755809T3 (es) 2013-03-15 2020-04-23 Janssen Pharmaceutica Nv Composición farmacéutica de hidrocloruro de S-ketamina
CN103655523A (zh) * 2013-12-24 2014-03-26 南京艾德凯腾生物医药有限责任公司 他喷他多组合物
MX2016014581A (es) * 2014-05-06 2018-02-16 Univ Northwestern Composiciones de compuestos que modulan nmdar.
JP6545788B2 (ja) 2014-08-13 2019-07-17 ヤンセン ファーマシューティカ エヌ．ベー． うつ病の治療方法
WO2016044150A1 (en) 2014-09-15 2016-03-24 Janssen Pharmaceutica Nv VAL66MET (SNP rs6265) GENOTYPE SPECIFIC DOSING REGIMENS AND METHODS FOR THE TREATMENT OF DEPRESSION
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
JP6845162B2 (ja) 2015-06-27 2021-03-17 シェノックス・ファーマシューティカルズ・エルエルシー ケタミン経皮送達システム
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
BR112020012473A2 (pt) 2017-12-22 2020-11-24 Janssen Pharmaceuticals, Inc. escetamina para o tratamento da depressão
AU2019253028B2 (en) 2018-04-12 2024-05-30 Anavex Life Sciences Corp. A2-73 crystalline polymorph compositions of matter and methods of use thereof
CN114126595A (zh) 2019-03-05 2022-03-01 杨森制药公司 用于治疗抑郁症的艾司氯胺酮

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3391142A (en) 1966-02-09 1968-07-02 Lilly Co Eli Adamantyl secondary amines
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US5472711A (en) 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
US5330761A (en) 1993-01-29 1994-07-19 Edward Mendell Co. Inc. Bioadhesive tablet for non-systemic use products
US5455046A (en) 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5399362A (en) 1994-04-25 1995-03-21 Edward Mendell Co., Inc. Once-a-day metoprolol oral dosage form
DE4426245A1 (de) * 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
US6248789B1 (en) * 1996-08-29 2001-06-19 Stuart L. Weg Administration of ketamine to manage pain and to reduce drug dependency
US6007841A (en) * 1998-03-13 1999-12-28 Algos Pharmaceutical Corporation Analgesic composition and method for treating pain
US7700122B1 (en) * 1998-07-16 2010-04-20 Memorial Sloan-Kettering Cancer Center Topical compositions comprising an opioid analgesic and an NMDA antagonist
DE10005302A1 (de) * 2000-02-07 2002-01-17 Gruenenthal Gmbh Substituierte 1,2,3,4-Tetrahydrochinolin-2-carbonsäurederivate
US20010036943A1 (en) 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
PE20030527A1 (es) * 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
DE10163421A1 (de) * 2001-12-21 2003-07-31 Gruenenthal Gmbh Verwendung von (+)-(1S,2S)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)phenol als Antiemetikum
JP2003201254A (ja) * 2001-12-28 2003-07-18 Hisamitsu Pharmaceut Co Inc 鎮痛剤活性増強剤の治療上有効な血中濃度を維持するための製剤
JP2003210254A (ja) * 2002-01-18 2003-07-29 Nihon Form Service Co Ltd 車椅子専用ラック
CN1691936A (zh) 2002-09-09 2005-11-02 恩多制药公司 立即释放和延长释放组合的镇痛药组合物
US7273889B2 (en) * 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
US20090082466A1 (en) * 2006-01-27 2009-03-26 Najib Babul Abuse Resistant and Extended Release Formulations and Method of Use Thereof
SI2012763T1 (sl) 2006-04-28 2011-06-30 Gruenenthal Gmbh Farmacevtska kombinacija, ki obsega 3-(3-dimetilamino-1-etil-2-metil- propil)-fenol in NSAID
US20070254960A1 (en) 2006-04-28 2007-11-01 Gruenenthal Gmbh Pharmaceutical combination
DE602007011913D1 (de) 2006-04-28 2011-02-24 Gruenenthal Gmbh Pharmazeutische kombination mit 3- (3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol und paracetamol
EP1857463A1 (en) 2006-05-03 2007-11-21 Ebewe Pharma Ges.m.b.H. Nfg. KG Peptide having neuroprotective effects
AU2007256352A1 (en) * 2006-06-08 2007-12-13 Ucb Pharma Gmbh Therapeutic combination for painful medical conditions
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
DE102007012165A1 (de) * 2007-03-12 2008-09-18 Grünenthal GmbH Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie des Neuropathieschmerzes
MX360289B (es) * 2007-11-23 2018-10-29 Gruenenthal Gmbh Composiciones de tapentadol.
JP5774853B2 (ja) 2008-01-25 2015-09-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 医薬投薬形
US7872046B2 (en) * 2008-01-25 2011-01-18 Xenoport, Inc. Crystalline form of a (3S)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use
US20100190752A1 (en) 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
SI2331210T1 (sl) * 2008-09-05 2014-10-30 Gruenenthal Gmbh Farmacevtska kombinacija 3-(3-dimetilamino-1-etil-2-metil-propil)-fenola in antiepileptika
US8846765B2 (en) * 2010-06-15 2014-09-30 Gruenenthal Gmbh Pharmaceutical combination
UY33618A (es) 2010-09-21 2012-03-30 Purdue Pharma Lp Analogos de buprenorfina
US8808740B2 (en) 2010-12-22 2014-08-19 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
RS54711B1 (sr) 2011-03-04 2016-08-31 Grünenthal GmbH Parenteralno davanje tapentadola
JP6279547B2 (ja) 2012-04-17 2018-02-14 パーデュー、ファーマ、リミテッド、パートナーシップ オピオイド誘発性有害薬力学的応答を治療するためのシステムおよび方法

Also Published As

Publication number Publication date
US20170333369A1 (en) 2017-11-23
US10813890B2 (en) 2020-10-27
AR081931A1 (es) 2012-10-31
KR20130111945A (ko) 2013-10-11
ES2560676T3 (es) 2016-02-22
US20110306674A1 (en) 2011-12-15
RU2016119041A (ru) 2017-11-20
CA2796774A1 (en) 2011-12-22
HK1184370A1 (zh) 2014-01-24
AU2016219643A1 (en) 2016-09-15
PT2582366E (pt) 2016-01-26
CY1117118T1 (el) 2017-04-05
JP6423036B2 (ja) 2018-11-14
ECSP19047259A (es) 2019-07-31
AU2011267474A1 (en) 2013-01-10
PE20160531A1 (es) 2016-06-05
US8846765B2 (en) 2014-09-30
CN103108631B (zh) 2015-08-26
RS54439B1 (sr) 2016-06-30
WO2011157391A1 (en) 2011-12-22
JP6197007B2 (ja) 2017-09-13
AU2016219643B2 (en) 2018-04-12
AU2011267474B2 (en) 2016-05-26
EP2582366A1 (en) 2013-04-24
HUE026619T2 (en) 2016-06-28
CA2796774C (en) 2020-06-02
HK1215787A1 (en) 2016-09-15
US20140309311A1 (en) 2014-10-16
RU2013101515A (ru) 2014-07-20
JP2013528629A (ja) 2013-07-11
RU2675261C2 (ru) 2018-12-18
NZ602625A (en) 2014-03-28
ZA201208646B (en) 2013-09-25
MX2012014482A (es) 2013-02-21
ECSP12012217A (es) 2012-11-30
CN103108631A (zh) 2013-05-15
DK2582366T3 (en) 2015-12-07
KR101831616B1 (ko) 2018-04-04
CL2012002551A1 (es) 2012-11-09
BR112012031836A2 (pt) 2016-11-08
JP2017141277A (ja) 2017-08-17
EP2582366B1 (en) 2015-10-28
PE20130243A1 (es) 2013-03-22
RU2589692C2 (ru) 2016-07-10
IL221926A (en) 2015-08-31
JP2015232015A (ja) 2015-12-24
JP6133772B2 (ja) 2017-05-24
EP2992877A1 (en) 2016-03-09
SI2582366T1 (sl) 2016-02-29
PL2582366T3 (pl) 2016-04-29
HRP20151327T1 (hr) 2016-01-01

Similar Documents

Publication Publication Date Title
ECSP19047259A (es) Combinación farmacéutica para el tratamiento del dolor
AR117613A2 (es) Combinación farmacéutica
UY35210A (es) Inhibidores de autotaxina
UY32925A (es) Composiciones de corticosteroides de administración oral
CL2015001389A1 (es) Composiciones y compuestos antihelmínticos y métodos para usarlos.
MX2015002378A (es) Composicion ansiolitica, formulacion y metodo de uso.
ECSP13013050A (es) Formulación para anticuerpo anti- 4 7
UY32819A (es) Composiciones farmaceuticas de uso oftalmico de antagonistas del receptor dp2
CL2013003527A1 (es) Compuestos heterociclicos antagonistas de los receptores muscarinicos y agonistas del receptor beta2 adrenergico; su composicion farmaceutica; su combinacion; un dispositivo y su uso en la prevencion y/o el tratamiento de enfermedades bronco-obstructivas o inflamatorias como asma y epoc.
CU20140068A7 (es) Triazolopiridinas sustituidas
CR20140182A (es) Nuevos derivados de ciclohexilamina que tienen actividad como agonistas adrenérgicos b2 y como antagonistas muscarínicos m3
CR20130569A (es) Análogos del ácido epoxieicosatrienoicos y métodos de toma y uso del mismo
ECSP14013340A (es) Nuevos derivados de ciclohexilamina que tienen actividad como agonistas adrenérgicos ?2 y como antagonistas muscarínicos m3
CR20130239A (es) Compuestos de triazolopiridina
MX2013015274A (es) Anatagonista trpm8 y su uso en tratamientos.
CR20150440A (es) Nuevos derivados de piridina
UY35199A (es) Nuevos derivados carbamato de ciclohexilo y quinuclidinilo que tienen actividad como agonistas beta2 adrenérgicos y como antagonistas muscarínicos M3
MX2017004440A (es) Una formulacion de rapamicina inhalable para el tratamiento de hipertension pulmonar.
MX2022001796A (es) Metodos y composiciones para inhibir los sintomas asociados con la veisalgia.
BR112015018200A2 (pt) composição mastigável para administração oral e processo para preparar a mesma
NZ711847A (en) Parasiticidal compositions comprising benzimidazole derivatives, methods and uses thereof
CO6341550A2 (es) Combinacion farmaceutica que contiene el 6 - dimetilaminometil - 1 - (3-metoxi-fenil) - ciclohexano - 1,3 - diol y un nsaid.
ECSP11010876A (es) Combinación farmacéutica que contiene el 6-dimetilaminometil-1-(3-metoxi-fenil)-ciclohexano-1,3-diol y paracetamol
MX376160B (es) Compuestos que tienen actividad antagonista del receptor muscarínico y actividad agonista del receptor beta2 adrenérgico.
GT201400115A (es) Combinación farmacéutica antineurítica y composición